Orcosa utilizes its Rapid Infusion Technology (RITe™) Platform to create orally disintegrating tablets that dissolve in under three seconds, enhancing the absorption of active ingredients through buccal tissue. This technology provides a non-addictive alternative for pain management, offering rapid effects and improved bioavailability compared to traditional opioid medications.
Funding
$18.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional oral medications for pain management, particularly opioids, can be addictive and have slow absorption rates, leading to delayed pain relief and potential for abuse. Many patients also experience difficulty swallowing pills or prefer faster-acting alternatives.
Solution
Orcosa is developing orally disintegrating tablets utilizing its Rapid Infusion Technology (RITe™) platform to address these issues. RITe™ tablets dissolve in under three seconds, enhancing the absorption of active pharmaceutical ingredients (APIs) through the buccal tissue in the cheek. This rapid absorption bypasses first-pass metabolism, potentially improving bioavailability and reducing the required dosage. Orcosa's lead program, ORAVEXX™ (cannabidiol), is being developed as a non-addictive alternative to opioids for managing pain and inflammation. The RITe™ platform aims to provide faster onset of action, improved patient experience, and reduced risk of adverse effects compared to conventional oral medications.
Target Audience
The primary target audience includes patients seeking non-addictive pain management solutions, individuals who have difficulty swallowing pills, and those who prefer faster-acting medications.
Features
- Rapid Infusion Technology (RITe™) platform for sublingual drug delivery
- Orally disintegrating tablets that dissolve in under 3 seconds
- Enhanced absorption of active ingredients through buccal tissue
- Potential for improved bioavailability and reduced dosage requirements
- ORAVEXX™ (cannabidiol) as a non-addictive alternative to opioid pain management
- Proprietary manufacturing process in a cGMP-compliant facility
- Collaborations with leading research institutions for clinical trials